Ischemic Colitis
- Home
- Solutions
- By Diseases
- Intestinal Diseases
- Ischemic Colitis
Ischemic colitis is the injury with the highest incidence within the gastrointestinal ischemic injuries and is due to inadequacy of blood supply to the colon. Protheragen has a rich background supported by a team of experts and industry veterans which aids in the drug research and development for ischemic colitis therapy. We pledge to advance your ischemic colitis drug research development with support services and bespoke solutions.
Ischemic colitis encompasses a range of syndromes arising from occlusive and nonocclusive vascular diseases.
Overall, the age-adjusted and sex-adjusted incidence rates of ischemic colitis in the general population were 16.3 per 100,000 persons. Individuals suffering from ischemic colitis may have symptoms including acute abdominal pain, hematochezia, and diarrhea. The broad overlap of symptoms including acute mesenteric ischemia, inflammatory bowel disease, or infectious bowel disease complicates the diagnostic process, and therapy may be delayed.
Fig.1 The most common sites for ischemic colitis. (Hung, A., et al., 2019)
The development of ischemic colitis is based on two different mechanisms which make the pathology of ischemic colitis widely diverse. The first and most frequent mechanism is the reduction of blood flow, which results in an imbalance between the blood supply to the bowel and its metabolic requirement. This non-occlusive form of dysregulation is seen in individuals with cardiac failure or shock - whether it is hypovolemic, hemorrhagic, or septic in origin. Other causes of non-occlusive ischemia are colonic obstruction due to volvulus, colon cancer, fecal impaction, strangulated hernia, or pseudoobstruction. In these conditions, blood flow is reduced as a consequence of gut distension due to rising intraluminal pressure.
Fig.2 The severity classification of ischemic colitis. (Xu, Y., et al., 2021)| Drug Names | Mechanism of Action | Targets | Research Phase |
| Polydeoxyribonucleotide | Elevating the expression of VEGF and suppressing inflammatory cytokines and COX-2 through elevation of A2AR expression. | A2AR | Preclinical |
| Mononuclear cell therapy | Potentiate not only tissue repair and blood vessel formation but also the formation of the nervous tissue. | / | Preclinical |
| Pentoxifylline | Favorably influences the hemodynamics in conjunction with vascular smooth muscle. | PDE | Preclinical |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Welcome to our premier research services firm that offers critically needed support in the study and development of drugs for ischemic colitis. With the sophistication of our facilities and equipment, we are enabled to perform high-precision experiments and log data of the highest quality. We offer a comprehensive service that integrates diagnostic, therapeutic, and disease model development services to elucidate the pathophysiology of ischemic colitis and hasten the discovery of effective interventions.
Using animal models of ischemic colitis allows for disease progression simulation, mechanistic studies, and novel therapy efficacy and safety evaluation. Our company specializes in developing animal models for ischemic colitis and is committed to creating specialized high-quality models to facilitate pharmaceutical research focusing on advanced therapy for ischemic colitis.
This model stems from surgery mirroring the Ischemia of the colon through the ligation of specific blood vessels that perfuse the colon.
The serosal surface of the proximal colon was irradiated using a krypton laser which was able to induce localized ulcers of the colon.
Embark on a transformative journey in ischemic colitis drug research with our comprehensive services such as pharmacokinetic research and drug safety evaluation services. At Protheragen, we intend to work together with you to realize mutually beneficial objectives that take your initiatives in ischemic colitis drug research to new levels. For specific information and pricing details, please do not hesitate to get in contact with us.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.